Online inquiry

IVTScrip™ mRNA-Anti-CD52, GZ-402668(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8015MR)

This product GTTS-WQ8015MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD52 gene. The antibody can be applied in Multiple sclerosis (MS) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_001803.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1043
UniProt ID P31358
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD52, GZ-402668(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ8015MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14696MR IVTScrip™ mRNA-Anti-MS4A1, SCT-400(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA SCT-400
GTTS-WQ9612MR IVTScrip™ mRNA-Anti-PDCD1, JNJ-63723283(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA JNJ-63723283
GTTS-WQ15046MR IVTScrip™ mRNA-Anti-CD47, SRF-231(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA SRF-231
GTTS-WQ15807MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, XmAb14045(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA XmAb14045
GTTS-WQ14596MR IVTScrip™ mRNA-Anti-CD38, SAR-650984(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA SAR-650984
GTTS-WQ2380MR IVTScrip™ mRNA-Anti-HGF, AMG 102(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 102
GTTS-WQ4051MR IVTScrip™ mRNA-Anti-IL36RN, BI 655130(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BI 655130
GTTS-WQ1480MR IVTScrip™ mRNA-Anti-CD79B, ACD79B-VCMMAE(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ACD79B-VCMMAE
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW